Guggenheim Reiterates Spyre Therapeutics as Top Pick Despite Halt of Arthritis Program

Guggenheim has reiterated its buy rating and designated Spyre Therapeutics (SYRE) as a top pick in the biotechnology sector, a move that comes despite the company's decision to discontinue a key monotherapy program. The firm's confidence is rooted in the broader potential of Spyre's drug pipeline, particularly in other inflammatory diseases.

Trial Results and Program Discontinuation

Spyre Therapeutics announced topline results from its Phase II SKYWAY-RA study evaluating SPY072, a TL1A-targeted therapy, in patients with rheumatoid arthritis (RA). While the trial was technically successful, demonstrating statistically significant efficacy improvements over placebo, Spyre determined the overall magnitude of the effect did not meet its internal threshold to justify further investment in a monotherapy approach for RA.

According to the company's announcement, the trial showed:

• Significant target engagement and numerically greater efficacy on key measures like ACR20/50/70.
• A safety profile consistent with the known TL1A class, with no drug-induced serious adverse events reported.

Despite these points, Spyre will not advance the SPY072 monotherapy program in rheumatoid arthritis.

Guggenheim's Rationale

Ad

Guggenheim's analysis suggests that market expectations for the RA trial were low to cautiously optimistic, and the firm's valuation of Spyre is not primarily dependent on this specific program. The investment firm attributes most of the company's value to its inflammatory bowel disease (IBD) pipeline, which has a major topline data readout for its SKYLINE-UC study expected in 2027.

The firm noted that the trial's success in the difficult-to-treat TNF-exposed patient population was a positive sign of the drug's potential. Guggenheim believes multiple opportunities remain for SPY072 in other inflammatory conditions and as part of combination therapies, including an ongoing Phase II program in hidradenitis suppurativa. The firm projects Spyre's stock will settle in the $90-95 range.

Broader Market Context

Analyst ratings on Spyre Therapeutics have been mixed recently. While Guggenheim and Stifel, which reiterated its Buy rating, remain positive, Wolfe Research recently downgraded the stock to "Peerperform" from "Outperform," citing valuation concerns.

In contrast, Mizuho raised its price target on Spyre to $120, referencing positive data from the company's core IBD program. This highlights a divergence in analyst focus, with bulls concentrating on the long-term potential of the IBD pipeline over the setback in the rheumatoid arthritis program.